Pilocarpine

• Description :

  Pilocarpine is a selective M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.

• UNSPSC :

  12352005

• Hazard Statement :

  H300+H330

• Target :

  MAChR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pilocarpine.html

• Purity :

  99.89

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1OC[C@H](CC2=CN=CN2C)[C@@H]1CC

• Molecular Formula :

  C11H16N2O2

• Molecular Weight :

  208.26

• Precautions :

  H300+H330

• References & Citations :

  [1]Matsuzaki K, et al. Daily voluntary exercise enhances pilocarpine-induced saliva secretion and aquaporin 1 expression in rat submandibular glands. FEBS Open Bio. 2017 Dec 7;8 (1) :85-93.|[2]Yuan XL, et al. Cytotoxicity of pilocarpine to human corneal stromal cells and its underlying cytotoxic mechanisms. Int J Ophthalmol. 2016 Apr 18;9 (4) :505-11.|[3]Tonta MA, et al. Pilocarpine-induced relaxation of rat tail artery by a non-cholinergic mechanism and in the absence of an intact endothelium. Br J Pharmacol. 1994 Jun;112 (2) :525-32.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  MAChR3

• Citation 01 :

  ACS Pharmacol Transl Sci. 2025 Jun 6;8 (7) :2048-2060.|BMC Immunol. 2024 Feb 12;25 (1) :16.|Cell Rep. 2023 Apr 30;42 (5) :112456.|FASEB J. 2024 Aug 15;38 (15) :e23878.|Int J Mol Sci. 2023 Apr 12;24 (8) :7171.|Int J Mol Sci. 2023 Apr 16;24 (8) :7356.|Int J Mol Sci. 2024 Sep 27;25 (19) :10432.|J Nanobiotechnology. 2025 Mar 20;23 (1) :228.|J Nanobiotechnology. 2025 May 5;23 (1) :332.|Life Sci. 2022 Nov 1;308:120942.|Mol Cell Endocrinol. 2025 Jan 21:599:112464.|Mol Immunol. 2024 Jun 19:172:68-75.|Neurochem Int. 2024 Mar:174:105677.|Ocul Surf. 2024 Oct:34:430-440.|Prog Neurobiol. 2022 Oct:217:102335.|Research Square Preprint. 2023 Apr 13.|Research Square Print. December 16th, 2022.|Sci Rep. 2025 Jul 15;15 (1) :25579.|Acta Pharmacol Sin. 2024 Dec;45 (12) :2611-2624.|Brain Res. 2023 Jul 1:1810:148382.|Brain Sci. 2023 Feb 3;13 (2) :262.|Cell Mol Neurobiol. 2022 Apr;42 (3) :777-790.|Cell Rep. 2025 Feb 23;44 (3) :115343.|Cells. 2024 Oct 1;13 (19) :1635.|Commun Biol. 2024 Sep 17;7 (1) :1158.|Epilepsia Open. 2025 Aug 28.|Epilepsy Res. 2018 May:142:45-52.|Exp Eye Res. 2024 Jul 16:110008.|Food Chem. 2022 Nov 30:395:133593.|Front Pharmacol. 2023 Jun 26:14:1191692. |Immunity. 2022 Aug 9;55 (8) :1466-1482.e9.|Int Immunopharmacol. 2022 Oct:111:109152.|Int Immunopharmacol. 2024 Feb 15:128:111485.|J Mol Neurosci. 2020 Nov;70 (11) :1858-1870.|Neuropharmacology. 2017 May 1:117:238-248.|Neuroscience. 2021 Feb 10;455:212-222.|Research Square Preprint. 2021 Aug.

• CAS Number :

  [92-13-7]